Anti-Idiotype Ankyrons™

a game-changer for developing assays to track target-specific antibodies

 

Take the pain out of targeting the idiotype of your antibodies

Detecting and targeting specific antibody idiotypes is key for developing effective tracking assays for drug antibodies. Developing monoclonal and eventually recombinant anti-drug idiotype antibodies for such purposes has been possible but time-consuming and expensive.

Ankyrons provide a clear and powerful solution to this problem. Selected directly in vitro from our Teralibrary we already offer a growing range anti-drug idiotype Ankyrons, including against already approved therapeutic antibodies for Herceptin® (trastuzumab), Erbitux® (cetuximab), Avastin® (bevacizumab), Humira® (adalimumab), and Rituxan® (rituximab). Using guided selection we are able to select idiotype-specific Ankyrons quickly confirming non-binding to unrelated drug antibodies and other Ig subtypes.

Contact us with your Custom Ankyron™ requirements or Request a Quote for us to make a quantum leap in your idiotype targeting project.

Data for Avastin® (bevacizumab) idiotype-specific Ankyron binding

Figure. Avastin® (bevacizumab) idiotype-specific Ankyron binding. Non-binding to other drug antibodies and Ig isotypes/sub-classes is shown at high signal-to-noise ratio.